TICKERNERD
Menu
XRAYXRAYHealthcare · Medical Instruments & Supplies

XRAY Stock Forecast: Dentsply Sirona, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$11
+1.16% on the day

The 18 Wall Street analysts covering Dentsply Sirona, Inc. hold a median 12-month price target of $14 — +28.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
91 / 100
Median analyst target
$14
Analysts covering
18
Total return, dividends reinvested
1W
−5.9%
1M
−20.1%
YTD
−4.6%
1Y
−19.5%
From 52W high
−25.7%
From 52W low
+13.1%
$10
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XRAY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dentsply Sirona, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Issuance
95
Accruals
93
Volatility
84
Growth
66
Revisions
61
Quality
58
Momentum
39
Size
35

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (39): The shares have been drifting down relative to others.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XRAY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XRAY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18Oct 25Jan 26Apr 26Jul 26XRAYHigh $17Median $14Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says18 analysts
4 Buy12 Hold2 Sell
Low $11Median $14High $17

The green dot is the last close — the median target sits +28.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 July 2026Piper SandlerMaintainsNeutral$13 → $14
9 July 2026BMO CapitalInitiatesMarket Perform—
4 June 2026BarclaysMaintainsUnderweight—
7 May 2026UBSMaintainsBuy—
6 May 2026MizuhoMaintainsNeutral—
15 Apr 2026CitigroupInitiatesSell—
2 Mar 2026Barrington ResearchMaintainsOutperform—
2 Mar 2026MizuhoMaintainsNeutral—
27 Feb 2026BairdMaintainsNeutral—
27 Feb 2026Evercore ISI GroupMaintainsIn-Line—
27 Feb 2026Wells FargoMaintainsEqual-Weight—
19 Feb 2026B of A SecuritiesUpgradeBuy—
3 Feb 2026UBSMaintainsBuy—
20 Jan 2026MizuhoMaintainsNeutral—
5 Jan 2026Barrington ResearchMaintainsOutperform—
16 Dec 2025BairdMaintainsNeutral—
16 Dec 2025Barrington ResearchMaintainsOutperform—
9 Dec 2025BarclaysInitiatesUnderweight—
10 Nov 2025Barrington ResearchMaintainsOutperform—
7 Nov 2025JP MorganMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XRAY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

XRAY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.9%
Analysts raising
9
Analysts cutting
2
Fundamentals

Dentsply Sirona, Inc. (XRAY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.6×

Cheaper than 88% of US stocks

Price / sales
0.6×

Cheaper than 80% of US stocks

Price / book
1.7×

Cheaper than 53% of US stocks

EV / EBITDA
8.1×

Cheaper than 45% of US stocks

Growth & margins
Revenue growth (YoY)
−4.1%

Higher than 21% of US stocks

Earnings growth (YoY)
−4.1%

Higher than 31% of US stocks

Gross margin
54.9%

Higher than 68% of US stocks

Operating margin
9.2%

Higher than 63% of US stocks

Net margin
−15.0%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−33.0%

Higher than 26% of US stocks

Return on assets
2.0%

Higher than 58% of US stocks

Dividend yield
5.9%

Higher than 85% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

XRAY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
XRAYDentsply Sirona, Inc.$2.2B
91
ATRCAtriCure, Inc.$2.5B
94
LMATLeMaitre Vascular, Inc.$1.9B
75
BLFSBioLife Solutions, Inc.$1.8B
91
AZTAAzenta, Inc.$1.7B
80
KMTSKestra Medical Technologies Ltd.$1.6B
21
WRBYWarby Parker, Inc.$3.3B
30

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dentsply Sirona, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XRAY news & analysis

New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence

PRNewsWire · 19 Aug 2026positive

Wellspect HealthCare, a Dentsply Sirona brand, announced the U.S. launch of the Surity™ Urinary Management System, an at-home urine collection device for people living with urinary incontinence. The launch completes the full Surity™ portfolio in the U.S., following the earlier introduction of the Surity™ Female and Male External Catheters.

Why it matters — The product launch expands Dentsply Sirona's urology portfolio in the U.S. market, broadening its offering for the urinary incontinence segment.

DENTSPLY SIRONA Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026negative

Dentsply Sirona reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis. The decline reflected lower volumes in several businesses and distributor inventory reductions in Europe as the company continued its turnaround plan.

Why it matters — The revenue decline highlights ongoing headwinds from lower volumes and European distributor inventory reductions during Dentsply Sirona's turnaround.

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Zacks Investment Research · 7 Aug 2026neutral

Dentsply Sirona reported second-quarter sales down 4.1%, with dental weakness offsetting growth in its Wellspect business. Despite the sales decline, the company beat earnings expectations, improved margins, and maintained its 2026 guidance, though the stock fell.

Why it matters — For XRAY watchers, the results show a mixed quarter where dental softness weighed on sales even as Wellspect growth, margin improvement, and maintained 2026 guidance offered some support.

Here's What Key Metrics Tell Us About Dentsply (XRAY) Q2 Earnings

Zacks Investment Research · 7 Aug 2026neutral

Zacks reports on Dentsply Sirona's Q2 earnings for the quarter ended June 2026, noting that headline numbers may be usefully compared against Wall Street estimates and the year-ago actuals to gain deeper insight into the company's performance.

Why it matters — The item highlights how investors tracking Dentsply can assess its quarterly results beyond headline figures by reviewing key metrics against consensus estimates and prior-year levels.

DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

The Q2 2026 earnings call transcript for DENTSPLY SIRONA Inc. (XRAY) was published on Seeking Alpha, covering the company's second-quarter 2026 results and management discussion.

Why it matters — XRAY watchers would rely on this transcript for management's direct commentary on the company's Q2 2026 performance and outlook.

FAQ

Frequently asked questions about XRAY stock

What is the XRAY stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Dentsply Sirona, Inc. have a median 12-month price target of $14, with estimates ranging from $11 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XRAY stock a buy right now?

Of the 18 analysts covering Dentsply Sirona, Inc., 4 rate it a Buy, 12 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Dentsply Sirona, Inc. 91 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XRAY?

As at 22 Aug 2026, Dentsply Sirona, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will XRAY stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +28.4% from the last close, and Ticker Nerd's factor model ranks Dentsply Sirona, Inc. 91 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XRAY stock forecast for 2030?

No analyst covering Dentsply Sirona, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XRAY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $17 over the next 12 months.

How has XRAY stock performed over the past year?

Dentsply Sirona, Inc. returned -19.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dentsply Sirona, Inc. do?

Dentsply Sirona Inc. develops, manufactures, and markets professional dental products and technologies worldwide.

What is the latest news on XRAY?

The most recent item we track (PRNewsWire, 19 Aug 2026): "New At-Home Surity™ Urinary Management System Designed to Provide Comfort and Reliable Care for People Living with Urinary Incontinence". Wellspect HealthCare, a Dentsply Sirona brand, announced the U.S. launch of the Surity™ Urinary Management System, an at-home urine collection device for people living with urinary incontinence. The launch completes the full Surity™ portfolio in the U.S., following the earlier introduction of the Surity™ Female and Male External Catheters.

Company

About Dentsply Sirona, Inc.

Dentsply Sirona Inc. develops, manufactures, and markets professional dental products and technologies worldwide. It specializes in dental equipment supported by cloud-enabled solutions, alongside dental consumables and healthcare products for urology and enterology. The company operates through four key segments: Connected Technology Solutions, which provides imaging equipment, motorized handpieces, treatment centers, intraoral scanners, 3D printers, and mills like CEREC for chairside restorations; Essential Dental Solutions, offering endodontic, restorative, and preventive consumables; Orthodontic and Implant Solutions, featuring digital implant systems and orthodontic products; and Wellspect Healthcare, delivering continence care solutions for urinary and bowel management. These offerings serve dental professionals, orthodontists, oral surgeons, and healthcare providers, enhancing diagnostics, treatments, and patient care in dentistry and related fields. Founded in 1899 and headquartered in Charlotte, North Carolina, Dentsply Sirona Inc. plays a vital role in advancing oral health technologies and specialized medical consumables.

CEO Mr. Daniel T. Scavilla · 14,000 employees · United States · https://www.dentsplysirona.com